FDA Delays Decision on Alzheimer ' s Hopeful Donanemab FDA Delays Decision on Alzheimer ' s Hopeful Donanemab

In an unexpected move, the FDA has decided to hold an advisory meeting of outside experts to discuss the efficacy and safety of donanemab for Alzheimer ' s disease.Medscape Medical News
Source: Medscape Psychiatry Headlines - Category: Psychiatry Tags: Neurology & Neurosurgery Source Type: news